← Leaderboards
Michael Mullan
Archer Pharmaceuticals, Inc.
$578,772
Attributed
$1,736,317
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $812.4K · FY2018–21$1M$750K$500K$250K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$1,736,317 · 1
By mechanism
R42$1,736,317 · 1
Top collaborators
- Bruce E Blough3 shared
- Daniel Paris3 shared
Most similar at Archer Pharmaceuticals, Inc.
Same institution · by research overlap
- Daniel Paris$653,772
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAbeta AccumulationAffinityChronicAbnormally Phosphorylated TauAffectAbeta SynthesisAging PopulationActive MethodCellsAmyloidAmyloid Beta-ProteinAnalogAntihypertensive AgentsCharacteristicsAbsorptionAttentionBaseBindingAllosteric SiteClinical DevelopmentBlood PressureBrainClinical Trials
Grant awards (3)
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$699,018
R42 · FY2021 · AG · contact PI
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$812,379
R42 · FY2020 · AG · contact PI
Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.$224,920
R42 · FY2018 · AG · contact PI